Clinical Trials Logo

Basal Cell Nevus Syndrome clinical trials

View clinical trials related to Basal Cell Nevus Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03767439 Withdrawn - Clinical trials for Basal Cell Nevus Syndrome

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Start date: July 2019
Phase: Phase 2
Study type: Interventional

This is a single-arm, phase II study to assess the efficacy of combined SMO and PD-1 inhibition with Vismodegib (SMO inhibitor) and Nivolumab (anti-PD-1 antibody) in BCNS patients (target enrollment of 22 patients), with a primary endpoint of 18-month disease control rate. The purpose of this study is to test the hypothesis that Nivolumab and Vismodegib will improve the percentage of BCNS patients who achieve disease control (defined as total tumor burden <50% of baseline) at 18 months from 50% to 80%. Baseline and on-treatment biopsies will be obtained to characterize the immune effects of combined SMO and PD-1 inhibition.

NCT ID: NCT03070691 Withdrawn - Clinical trials for Basal Cell Carcinoma

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks. Treatment success is defined as complete clinical clearance and complete histological clearance in BCCs.